- Pluristem Therapeutics (NASDAQ:PSTI +0.3%) announces that it has received notice from United Therapeutics (UTHR +1.9%) that it is terminating its license agreement for cell therapy PLX-PAD for the treatment of pulmonary arterial hypertension. Full rights to the product candidate will revert back to Pluristem.
- A small Phase 1 study conducted by United in September 2014 showed an encouraging but limited efficacy trend.